J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
